The Pharmacist's Role in New Acute Myeloid Leukemia Treatments
by Maximilian Vitas, 2022 PharmD Candidate, Shujie Lin, 2022 PharmD Candidate, Rucha Kulkarni, 2023 PharmD Candidate
"Newly approved agents such as gemtuzumab, midostaurin, gilteritinib, and venetoclax have created a shift in current treatment practices for acute myeloid leukemia (AML). These agents have evidence for improving AML patient outcomes and act as targeted therapy for specific AML subtypes. Pharmacists hold critical roles in evaluating the safety and use of these new agents as well as the cancer continuum of AML."
Keywords: Pharmacists, Survival Rate, Incidence, Public Health, Wisconsin, Bridged Bicyclo Compounds, Heterocyclic, Pyrazines, Sulfonamides, Aniline Compounds, Health Care Costs, Delivery of Health Care, Health Services, Leukemia, Myeloid, Acute, Myeloid Progenitor Cells, Patient Care Team, Outcome Assessment, Health Care
Download PDF
2021 September/October Table of Contents
"Newly approved agents such as gemtuzumab, midostaurin, gilteritinib, and venetoclax have created a shift in current treatment practices for acute myeloid leukemia (AML). These agents have evidence for improving AML patient outcomes and act as targeted therapy for specific AML subtypes. Pharmacists hold critical roles in evaluating the safety and use of these new agents as well as the cancer continuum of AML."
Keywords: Pharmacists, Survival Rate, Incidence, Public Health, Wisconsin, Bridged Bicyclo Compounds, Heterocyclic, Pyrazines, Sulfonamides, Aniline Compounds, Health Care Costs, Delivery of Health Care, Health Services, Leukemia, Myeloid, Acute, Myeloid Progenitor Cells, Patient Care Team, Outcome Assessment, Health Care
Download PDF
2021 September/October Table of Contents